| http://www.w3.org/ns/prov#value | - The pathway was created in the Biologics Price Competition and Innovation Act of 2009 but has taken several years to come to fruition, with the latest clarification of terms in May this year.The decision is an important step for biosimilars in the US, which is behind markets such as South Korea and Europe where cheaper copies of off-patent biological treatments are more available.Mark McCamish, he
|
